Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes. The ALLG MDS4 phase II trial randomized such patients to standard azac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenealy, Melita, Hertzberg, Mark, Benson, Warwick, Taylor, Kerry, Cunningham, Ilona, Stevenson, Will, Hiwase, Devendra, Eek, Richard, Zantomio, Daniela, Jong, Steve, Wall, Meaghan, Blombery, Piers, Gerber, Tracey, Debrincat, Marlyse, Zannino, Diana, Seymour, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442982/
https://www.ncbi.nlm.nih.gov/pubmed/30545923
http://dx.doi.org/10.3324/haematol.2018.201152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442982/
https://www.ncbi.nlm.nih.gov/pubmed/30545923
http://dx.doi.org/10.3324/haematol.2018.201152

Ejemplares similares